search
Back to results

Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension

Primary Purpose

Essential Hypertension

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Thiazide and beta blocker
Sponsored by
University of Cambridge
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Essential Hypertension focused on measuring Essential hypertension, Glucose metabolism, Thiazides, Beta blockers

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Volunteers will be aged 18-75 years.
  • Hypertension- either

    • untreated, BP 140-170/90-110
    • treated for over 1 month with drugs other than beta blockers or diuretic and BP>140/85
    • treated for over 1 month with drugs other than beta blockers or diuretic and BP<140/85 and patient willing to change medication for eight months.

Exclusion criteria:

  • Any patient already taking thiazide diuretics or beta blockers in whom these drugs cannot be switched to alternative drugs with similar or better blood pressure control.
  • Any patient who is intolerant of these medications will be excluded from the study.
  • Patients with gout, asthma or any other contraindications to the study drugs will be excluded.
  • Women of child bearing age not using contraception.
  • Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g. cancer)
  • Volunteers not able to give informed consent
  • Patients with diabetes

Sites / Locations

  • Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes HospitalRecruiting

Outcomes

Primary Outcome Measures

Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?

Secondary Outcome Measures

Do patients show a similar change in glucose tolerance after thiazide or beta blocker therapy?
Does the combination of drugs cause a greater reduction in glucose tolerance than expected from the response to each drug taken alone?

Full Information

First Posted
September 22, 2006
Last Updated
September 22, 2006
Sponsor
University of Cambridge
Collaborators
Cambridge University Hospitals NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT00380289
Brief Title
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
Official Title
Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
September 2006
Overall Recruitment Status
Unknown status
Study Start Date
September 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
University of Cambridge
Collaborators
Cambridge University Hospitals NHS Foundation Trust

4. Oversight

5. Study Description

Brief Summary
Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?
Detailed Description
We will be comparing the two most commonly used drugs to treat hypertension, atenolol and bendrofluazide, in patients for whom the drugs (and the doses to be used) are licenced. We propose an initial open label pilot study of 10-12 patients to confirm final doses to be tested, the duration of therapy for optimum timing of the OGTT and tolerability of doses selected. The pilot study will also be used to confirm sample size calculations for the main study.The protocol for the pilot study will be identical to the main study, but there will not be a placebo phase and the treatment will not be blinded. The main study will be double-blind, placebo controlled, cross-over study, of approximately 66 patients in which each patient receives in random order, 4 weeks treatment with either Bendrofluazide 5-10mg daily, Atenolol 50-100mg daily or combination of Bendrofluazide 2.5-5mg and Atenolol 25-50mg daily. There will be a forced titration from the lower to the higher dose stated half way through each dosing period. There will be a 1 month placebo wash-out between each dosing period. At 0, 2 and 4 weeks of each treatment phase, patients will attend the Clinical Investigation Ward (CIW), fasting, for performance of an oral glucose tolerance test (OGTT). Blood will be drawn from an intravenous cannula, for the measurements of glucose and insulin at 0, 0.5, 1 and 2 hours. Blood pressure will be measured at each study visit using an Omron machine. The patients will also be given a blood pressure machine to take home and will be asked to measure and record their blood pressure at least twice per week. If their blood pressure is under 110/70mmhg or over 160/110mmHg at any time or if the patient has symptoms e.g. headache or dizziness, the patient will be asked to contact study staff. If the blood pressure remains over 160/110 for two measurements, then another antihypertensive therapy may be commenced, or the patient withdrawn from the study. If blood pressure is < 110/70 mmHg with symptoms then a decision may be made to terminate their participation in the study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Essential Hypertension
Keywords
Essential hypertension, Glucose metabolism, Thiazides, Beta blockers

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
66 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Thiazide and beta blocker
Primary Outcome Measure Information:
Title
Can the oral glucose tolerance test detect changes after 4 weeks treatment with thiazide diuretics or beta blockers or combination of the two?
Secondary Outcome Measure Information:
Title
Do patients show a similar change in glucose tolerance after thiazide or beta blocker therapy?
Title
Does the combination of drugs cause a greater reduction in glucose tolerance than expected from the response to each drug taken alone?

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Volunteers will be aged 18-75 years. Hypertension- either untreated, BP 140-170/90-110 treated for over 1 month with drugs other than beta blockers or diuretic and BP>140/85 treated for over 1 month with drugs other than beta blockers or diuretic and BP<140/85 and patient willing to change medication for eight months. Exclusion criteria: Any patient already taking thiazide diuretics or beta blockers in whom these drugs cannot be switched to alternative drugs with similar or better blood pressure control. Any patient who is intolerant of these medications will be excluded from the study. Patients with gout, asthma or any other contraindications to the study drugs will be excluded. Women of child bearing age not using contraception. Volunteers with heart failure, liver failure, renal failure, terminal illnesses (e.g. cancer) Volunteers not able to give informed consent Patients with diabetes
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Professor MJ Brown, MA MSC MD FRCP
Phone
01223 762577 (UK)
Email
mjb14@medschl.cam.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Dr A Stears, MBBS BSc MRCP
Phone
01223 586865 (UK)
Email
as659@medschl.cam.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Professor MJ Brown, MA MSC MD FRCP
Organizational Affiliation
Addenbrookes Hosptal NHS Trust/ University of Cambridge
Official's Role
Principal Investigator
Facility Information:
Facility Name
Clinical Pharmacology Unit, Box 110, Level 3 ACCI, Addenbrookes Hospital
City
Cambridge
ZIP/Postal Code
CB2 2QQ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mrs M Watts
Phone
01223 586865
Email
mw363@medschl.cam.ac.uk
First Name & Middle Initial & Last Name & Degree
Dr A Stears, MBBS BSc MRCP
Phone
01223 586878
Email
as659@medschl.cam.ac.uk

12. IPD Sharing Statement

Citations:
PubMed Identifier
22493073
Citation
Stears AJ, Woods SH, Watts MM, Burton TJ, Graggaber J, Mir FA, Brown MJ. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension. 2012 May;59(5):934-42. doi: 10.1161/HYPERTENSIONAHA.111.189381. Epub 2012 Apr 9.
Results Reference
derived

Learn more about this trial

Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension

We'll reach out to this number within 24 hrs